Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy
Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adop...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 July 2022
|
| In: |
Clinical drug investigation
Year: 2022, Volume: 42, Issue: 8, Pages: 643-656 |
| ISSN: | 1179-1918 |
| DOI: | 10.1007/s40261-022-01173-3 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40261-022-01173-3 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s40261-022-01173-3 
|
| Author Notes: | Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli |
| Summary: | Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adoption to clinical practice. |
|---|---|
| Item Description: | Gesehen am 24.10.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1179-1918 |
| DOI: | 10.1007/s40261-022-01173-3 |